1-8 of 8
Christopher Pocock, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML

Stephen O'Brien, MBBS, BSc, PhD MRCPath, MRCP, Leanne Cork, BSc, Valeria Bandeira, MD, Ruth Bescoby, MSc, Letizia Foroni, MD PhD, Lynn Alaily, MSc, RN, NDN, MICR, Wendy Osborne, MBBS, Helen Bell-Gorrod, BSc, Nicholas Latimer, PhD, Jane Apperley, MB ChB MD, Corinne Hedgley, BSc (Hons), Richard Syzdlo, PhD, Jennifer Byrne, MB, ChB, MRCP, MRCPath, MD, Christopher Pocock, MD PhD, Bernard Ramsahoye, MB, ChB, PhD FRCPath, MRCP, Thomas Zwingers, BSc, James Wason, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 457.
https://doi.org/10.1182/blood-2018-99-110128
Published: 2018
Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 396.
https://doi.org/10.1182/blood-2018-99-115930
Published: 2018
Journal Articles

Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Steven Knapper, DM, Michael Dennis, MD, MRCP, FRCPath, Mark W Drummond, PhDMD, Robert K. Hills, MA, DPhil, MSc, Richard James Dillon, MA, PhD MRCP, FRCPath, Christopher Pocock, MD PhD, Dominic J. Culligan, Paresh Vyas, Daniel Wiseman, MB, ChB, Joanna Zabkiewicz, PhD, Marie Hodges, PhD MSc, Catherine Cargo, MB, FRCPath, Jan Taylor, PhD MSc, BSc, Laura Upton, Melissa Wright, David Bowen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1818.
https://doi.org/10.1182/blood-2018-99-110356
Published: 2018
Journal Articles

Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study

Andrew M. Evens, DO, MSc, Joseph M. Connors, MD, Anas Younes, MD, Stephen M. Ansell, MD PhD, Won Seog Kim, MD PhD, John Radford, MD FRCP, Tatyana A. Feldman, MD, Joseph Tuscano, Kerry J Savage, BSc, MD MSc, Yasuhiro Oki, MD, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Christopher Pocock, MD PhD, Monika Dlugosz-Danecka, MD PhD, Keenan Fenton, Gerald Engley, PharmD, Rachael Liu, PhD, Harry Miao, MD, Hina Jolin, Pharm D, Ashish Gautam, PhD MBA, Andrea Gallamini, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1618.
https://doi.org/10.1182/blood-2018-99-112178
Published: 2018
Journal Articles

A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial

Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza Hawkes, Anthony Lawrie, Andrew Jack, Paul Smith, Christopher Pocock, MD PhD, Kirit M. Ardeshna, MB BChir, John Radford, MD FRCP, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, MD, David C. Linch
Journal: Blood
Blood (2018) 132 (Supplement 1): 2956.
https://doi.org/10.1182/blood-2018-99-111824
Published: 2018
Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jacqueline C. Barrientos, MD, Susan O'Brien, Jennifer R. Brown, MD PhD, Neil E. Kay, MD, Nishitha M. Reddy, MBBS, Steven Coutre, MD, Constantine Tam, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Ulrich Jaeger, MD, Steve Devereux, MD, Christopher Pocock, MD PhD, Tadeusz Robak, MD, Stephen J. Schuster, MD, Anna Schuh, MDPhD, Devinder Gill, MD, Adrian Bloor, PhD FRCPath, Claire Dearden, MD, Carol Moreno, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Michael Hamblin, Jeffrey A. Jones, MD, Tanja Kierschniak, Karl Eckert, BA, Samuel Suzuki, MS, MBA, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD, Peter Hillmen, MB, ChB, PhD
Journal: Blood
Blood (2014) 124 (21): 4696.
https://doi.org/10.1182/blood.V124.21.4696.4696
Published: 2014
Journal Articles

Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial

Mary Gleeson, FRCPath, David Cunningham, FMedSci, Eliza A Hawkes, MD, Wendi Qian, PhD, Paul Smith, MSc, Nick Chadwick, Paul Mouncey, MSc, Andrew Jack, PhD, Christopher Pocock, MD PhD, Kirit M Ardeshna, MD FRCPath, John Radford, Andrew McMillan, PhD, John Davies, FRCPE, Deborah Turner, FRCPath, Anton Kruger, FRCPath, Peter W.M. Johnson, FRCP, Joanna Gambell, BSc, David C Linch, FMedSci
Journal: Blood
Blood (2014) 124 (21): 1723.
https://doi.org/10.1182/blood.V124.21.1723.1723
Published: 2014
Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD
Journal: Blood
Blood (2014) 124 (21): 517.
https://doi.org/10.1182/blood.V124.21.517.517
Published: 2014